Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some claims align with the label (e.g., grapefruit juice CYP3A4 inhibition increasing atorvastatin concentrations; increased concentrations increasing myopathy risk). However, several statements are unsupported or not substantiated by the provided label excerpts (e.g., red wine/resveratrol interactions; patent expiration; generic availability; kidney problems risk; myopathy study claim; generic/red wine caution).
Category Scores
Accurate Statements
Grapefruit and grapefruit juice inhibit the enzyme CYP3A4 responsible for metabolizing Lipitor.
SECTION 7.2 Grapefruit Juice: 'Contains one or more components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin...'
Consuming grapefruit or grapefruit juice with Lipitor can lead to increased levels of Lipitor in the blood.
SECTION 7.2 Grapefruit Juice: '...can increase plasma concentrations of atorvastatin... especially with excessive grapefruit juice consumption (>1.2 liters per day).'
Increased Lipitor levels can increase the risk of muscle damage.
SECTION 7 (Drug Interactions) and SECTION 5.1 Skeletal Muscle: label describes increased risk of myopathy/rhabdomyolysis with factors that increase statin exposure (e.g., CYP3A4 inhibitors) and notes 'Rare cases of rhabdomyolysis...'
Unsupported Statements
Lipitor reduces bad cholesterol and triglycerides in the blood.
While the label excerpt in SECTION 12.1 says 'LIPITOR lowers plasma cholesterol and lipoprotein levels' and SECTION 1.2 references reducing LDL-C and TG, the provided user statement specifically 'bad cholesterol and triglycerides in the blood' is not explicitly phrased/confirmed in the excerpts as stated.
Increased Lipitor levels can increase the risk of kidney problems.
SECTION 5.1 links rhabdomyolysis with acute renal failure secondary to myoglobinuria, but the user statement attributes 'kidney problems' broadly to increased Lipitor levels; the provided excerpts do not directly state that increased plasma concentrations themselves cause kidney problems.
Red wine contains polyphenols such as resveratrol that can interact with statins like Lipitor.
No red wine/resveratrol interaction is described in the provided label excerpts.
A study found that consuming red wine with statins increased the risk of myopathy (muscle damage).
No such study or red wine-related myopathy finding is provided in the supplied label excerpts.
Lipitor's patent expired in 2017.
No patent/market exclusivity information is provided in the supplied label excerpts.
Generic versions of Lipitor are available.
No generic availability information is provided in the supplied label excerpts.
Generic Lipitor may interact with red wine in a similar manner to the brand-name version.
No red wine interaction is described in the provided label excerpts, so this cannot be supported.
Patients taking generic Lipitor should still exercise caution when consuming red wine.
No guidance about red wine for Lipitor/atorvastatin (brand or generic) is present in the provided label excerpts.
Contradictions
Important Omissions
Clarifying that grapefruit juice interaction is specifically associated with strong CYP3A4 inhibition and 'especially with excessive grapefruit juice consumption (>1.2 liters per day)'
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Grapefruit-related interaction and increased atorvastatin exposure increasing myopathy risk are supported. However, additional unsupported claims about red wine and kidney problems could mislead risk perception; grapefruit details (dose/excess amount) were not specified.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several statements (red wine/resveratrol, red wine study, patent/generic availability, kidney problems attribution, generic-to-brand interaction equivalence) are not supported by the provided label excerpts.
Suggested Improvement
Limit interaction claims to those supported by the label excerpts (e.g., grapefruit juice/CYP3A4 inhibition and increased atorvastatin plasma concentrations; risk framing tied to myopathy). Avoid including patent/generic availability and red wine/resveratrol claims unless explicitly supported in the provided label text. Include the label’s qualifier for grapefruit intake (excessive >1.2 L/day) if making this interaction statement.